Longitudinal changes in circulating RNA levels are only weakly correlated with disease progression in Huntington’s disease.
Why this matters
More sensitive, robust and objective ways of monitoring Huntington’s disease progression are urgently needed to improve prognosis. This is the first longitudinal analysis in a single Huntington’s disease cohort to identify novel transcriptional Huntington’s disease biomarkers and test previously reported candidates. The findings suggest that circulating RNA levels are poor candidates as disease biomarkers.